Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460304 | 1.00 | PKM (0.35) | PKMCA2CA1CA9METAP2 | |
| SCHEMBL1648065 | 0.85 | ALDH1A1 (0.37) | METAP2TSHR | |
| SCHEMBL12729386 | 0.85 | ALDH1A1 (0.37) | METAP2TSHR | |
| SCHEMBL454715 | 0.83 | CA1 (0.35) | CA2CA1CA9 | |
| SCHEMBL404047 | 0.83 | CA1 (0.35) | CA2CA1CA9 | |
| SCHEMBL14389032 | 0.83 | CA1 (0.35) | CA2CA1CA9 | |
| SCHEMBL14362931 | 0.82 | METAP2 (0.37) | METAP2 | |
| SCHEMBL2456071 | 0.79 | CA2 (0.36) | CA2CA1CA9MMP1MMP3 | |
| SCHEMBL12411311 | 0.73 | NT5E (0.36) | METAP2 | |
| SCHEMBL12233109 | 0.73 | CA1 (0.37) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | PKM 4229/4885CA2 268/4885CA1 121/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | PKM 4216/4885CA2 273/4885CA1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.